Glowacki Joseph, Holland Gregory, Graham Colleen, Bakhsh Khazenay
Internal Medicine, Rowan University School of Osteopathic Medicine, Stratford, USA.
Pulmonology, Jefferson Health New Jersey, Turnersville, USA.
Cureus. 2022 Jun 12;14(6):e25871. doi: 10.7759/cureus.25871. eCollection 2022 Jun.
Lymphangioleiomyomatosis (LAM) is a rare disorder that can cause lesions that develop into cysts, most commonly in the lung parenchyma and renal angiomyolipomas. We report a case of a young female with LAM who was admitted to the hospital for a COVID-19 infection, with the objective of discussing the management of LAM with concurrent COVID-19 infection. She ultimately showed overall clinical improvement after receiving dexamethasone and remdesivir, while holding her outpatient mammalian target of rapamycin (mTOR) inhibitor. When patients with rare diseases acquire COVID-19, an individualized approach to treatment is often most effective as information and studies may be limited.
淋巴管平滑肌瘤病（LAM）是一种罕见疾病，可导致形成囊肿的病变，最常见于肺实质和肾血管平滑肌脂肪瘤。我们报告一例患有LAM的年轻女性因COVID-19感染入院的病例，目的是讨论LAM合并COVID-19感染的治疗方法。她在接受地塞米松和瑞德西韦治疗后，同时停用门诊使用的哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂，最终总体临床症状得到改善。当罕见病患者感染COVID-19时，由于相关信息和研究可能有限，个体化治疗方法往往最为有效。
